A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria - Trial 2021-002071-19
Access comprehensive clinical trial information for 2021-002071-19 through Pure Global AI's free database. This phase not specified trial is sponsored by BAYER AG and is currently Ongoing. The study focuses on Chronic kidney disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2021-002071-19
Ongoing
Trial Details
EU Clinical Trials Register • 2021-002071-19
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
Study Focus
Sponsor & Location
BAYER AG
Bayer AG
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Mean reduction from baseline to Month 6 in Urinary Protein-to-Creatinine Ratio
ICD-10 Classifications
Chronic kidney disease
Chronic kidney disease, unspecified
Chronic kidney disease, stage 1
Chronic kidney disease, stage 4
Chronic kidney disease, stage 2
Data Source
EU Clinical Trials Register
2021-002071-19
Non-Device Trial